Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies. - Wikidata - wikimedia - TriplyDB

Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.

Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.

http://www.wikidata.org/entity/Q35538419

about

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment.Myeloid neoplasms with germ line RUNX1 mutation.Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing.MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms.

P2860

Q26749870-9232903D-C532-4C71-BE76-7D5D200F64F5 Q37609224-A01C00C9-D5E2-44A7-8DCD-85E86E8CA157 Q37662400-4C8D0215-347A-4DF3-9A71-135D34282BEE Q38451022-A1485452-FA34-4ABB-928A-C79F62C499F7 Q39324039-BB3244CD-94FD-4988-BBCE-5A1359E16511 Q47130430-B157394F-BD6F-4052-9C0E-28F9F19CC15C Q48181306-1D17C796-A704-4609-AEE7-F3200F1B64B2 Q55121930-FBD8426C-DE6D-4965-A92C-9C4DB1F0BA92

P2860

Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.

http://www.wikidata.org/entity/Q35538419

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Recent advances in myelodyspla ...... ations for targeted therapies.

@ast

Recent advances in myelodyspla ...... ations for targeted therapies.

@en

type

label

Recent advances in myelodyspla ...... ations for targeted therapies.

@ast

Recent advances in myelodyspla ...... ations for targeted therapies.

@en

prefLabel

Recent advances in myelodyspla ...... ations for targeted therapies.

@ast

Recent advances in myelodyspla ...... ations for targeted therapies.

@en

P1433

Q35538419-07A98DBA-3001-4426-A1D9-98FF542FB855

P1476

Q35538419-D014CFB8-1257-4F2B-9E3A-FB7E7E994F16

P2093

Q35538419-AC30FE7B-3C96-43D1-B81B-AACD72673092

Q35538419-C0213C57-515B-4E8F-AB64-ADCB304ACB08

P275

Q35538419-A53D8CD8-DE16-4344-8831-379B98068B84

P2860

Q35538419-01D50EE0-F3DE-4508-B5B4-C8565A38F5AF

Q35538419-0277ECAE-B25E-4FDD-9405-A947A6C9FB6C

Q35538419-044A0385-5BD0-4C0F-9781-FD9E3139B519

Q35538419-1598DDD5-EE1E-4939-A8AE-C8291222C9C6

Q35538419-175B39F0-9B5C-40E1-8FA0-D9D817516259

Q35538419-17644728-F383-49BD-8634-48145B240848

Q35538419-1F71262A-4C85-4F89-86D0-B03EBF644481

Q35538419-23841B6D-5661-4017-9EB2-2E33C004268D

Q35538419-249C8264-FFE3-42CF-953B-19419B80AB4E

Q35538419-2832F6FD-A976-4FDA-A9D8-FD2718F4EE31

P304

Q35538419-0FB8EFFF-257E-4D8F-AAE9-DA75DDEE5411

P31

Q35538419-93789FBB-1C99-4798-90E7-3D4BB9725D57

Q35538419-DF39F148-8F86-49B0-9118-868ACBB05EC3

P356

Q35538419-D66C5D6C-ED94-4F12-81AA-9A662D46615F

P433

Q35538419-24BE40A6-6D6B-4C13-A7B3-A095BD599D9A

P478

Q35538419-EEF51E20-4628-4208-8036-616A6053C2B7

P577

Q35538419-5FD87EC7-9C92-48C6-A3C0-8286AEC7D202

Q35538419-9E93E51C-F3AD-4B5C-90A2-E41C2C95AFB0

P5875

Q35538419-52C16F97-F2E5-4192-A649-D98641C355BD

P698

Q35538419-AA6DA65A-2ECE-42A3-80F6-83873A067EC2

P921

Q35538419-1CDD82E9-1D71-4499-8B66-948D6B8E62B8

Q35538419-BFCB33EF-2A3B-4CBF-8CDE-B1D2A5E7D8F3

P932

Q35538419-82218869-6AAE-4053-97B0-88506FEE8668

P356

P1433

P1476

Recent advances in myelodyspla ...... ations for targeted therapies.

@en

P2093

Hironori Harada

http://www.w3.org/2001/XMLSchema#string

Yuka Harada

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

P2860

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Asyn-anticonformational difference allows SRSF2 to recognize guanines and cytosines equally well

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

Age-related mutations associated with clonal hematopoietic expansion and malignancies

Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

Frequent pathway mutations of splicing machinery in myelodysplasia

P304

329-336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.12614

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271221736

http://www.w3.org/2001/XMLSchema#string

P698

25611784

http://www.w3.org/2001/XMLSchema#string

P921

myelodysplastic syndrome

P932

4409874

http://www.w3.org/2001/XMLSchema#string